Jamie Michael
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Michael has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Ashley E. Ross
3 shared publicationsDiana K. Bowen
Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
3 shared publicationsElizabeth B. Yerkes
Division of Urology, Ann & Robert H. Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Chicago, IL 60611, USA
3 shared publicationsAidan Raikar
Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publicationsAmy Krambeck
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, USA
2 shared publicationsClayton Neill
2 shared publications
Latest Publications
- 6 October 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1) , 106315
Constipation status and the enhanced recovery pathway in bladder reconstruction
- 6 October 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 23 (1) , 106315
Constipation status and the enhanced recovery pathway in bladder reconstruction
- 11 September 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 1061-1066
Cryoablation for localized prostate cancer: Feasibility in large prostates
- 11 September 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 1061-1066
Cryoablation for localized prostate cancer: Feasibility in large prostates
- Open Access
- 27 August 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (9) , e70259
Salvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer
Objectives: The purpose of this study is to evaluate salvage treatment after primary radiation therapy (RT) for prostate cancer within our hospital system. Specifically, we aim to evaluate treatment patterns, oncologic outcomes and complications. Materials and methods: We retrospectively identified men with post‐RT recurrence treated with salvage radical prostatectomy (sRP), seminal vesiculectomy, cryoablation, high‐dose‐rate brachytherapy (HDR) or irreversible electroporation (IRE). Salvage failure was defined as biochemical recurrence (BCR; Phoenix criteria, nadir + 2 ng/mL for cryoablation, HDR and IRE or prostate‐specific antigen (PSA) > 0.2 ng/mL for sRP and seminal vesiculectomy) or need for subsequent therapy. Cox regression identified factors associated with time to failure. Results: Seventy‐one patients underwent salvage therapy after RT; 58 (81.7%) cryoablation, 7 (9.9%) sRP, 2 (2.8%) robotic seminal vesiculectomies, and 4 (5.6%) other modalities. Failure occurred in 30 (45%) patients at a median of 12.5 months (IQR 6, 23). Grade group (GG) 4–5 disease prior to RT was associated with time to failure (HR 2.18, 95% CI 0.96, 4.97, p = 0.063) on multivariable analysis; however, the difference was not significant. Treatment type was not significantly associated with failure‐free survival ( p = 0.7). Four patients experienced Clavien–Dindo grade III or higher complications: three following sRP (two anastomosis dehiscence, clot retention) and one following cryoablation (stricture). Ten patients (14%) underwent local salvage for prostate recurrences in the setting of N1/M1 disease with concurrent systemic therapy, with no treatment escalation or complications at median 16 months follow‐up time. Conclusions: In this institutional cohort, salvage cryoablation demonstrated an acceptable short‐term failure‐free survival with fewer observed high‐grade complications than salvage prostatectomy. Salvage cryoablation also appeared feasible in select patients with low‐volume nodal or metastatic disease. These findings are hypothesis‐generating and require prospective validation.
- 27 August 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (9) , e70259
Open AccessSalvage prostate therapies for local pelvic recurrence after primary radiation for prostate cancer
Objectives: The purpose of this study is to evaluate salvage treatment after primary radiation therapy (RT) for prostate cancer within our hospital system. Specifically, we aim to evaluate treatment patterns, oncologic outcomes and complications. Materials and methods: We retrospectively identified men with post‐RT recurrence treated with salvage radical prostatectomy (sRP), seminal vesiculectomy, cryoablation, high‐dose‐rate brachytherapy (HDR) or irreversible electroporation (IRE). Salvage failure was defined as biochemical recurrence (BCR; Phoenix criteria, nadir + 2 ng/mL for cryoablation, HDR and IRE or prostate‐specific antigen (PSA) > 0.2 ng/mL for sRP and seminal vesiculectomy) or need for subsequent therapy. Cox regression identified factors associated with time to failure. Results: Seventy‐one patients underwent salvage therapy after RT; 58 (81.7%) cryoablation, 7 (9.9%) sRP, 2 (2.8%) robotic seminal vesiculectomies, and 4 (5.6%) other modalities. Failure occurred in 30 (45%) patients at a median of 12.5 months (IQR 6, 23). Grade group (GG) 4–5 disease prior to RT was associated with time to failure (HR 2.18, 95% CI 0.96, 4.97, p = 0.063) on multivariable analysis; however, the difference was not significant. Treatment type was not significantly associated with failure‐free survival ( p = 0.7). Four patients experienced Clavien–Dindo grade III or higher complications: three following sRP (two anastomosis dehiscence, clot retention) and one following cryoablation (stricture). Ten patients (14%) underwent local salvage for prostate recurrences in the setting of N1/M1 disease with concurrent systemic therapy, with no treatment escalation or complications at median 16 months follow‐up time. Conclusions: In this institutional cohort, salvage cryoablation demonstrated an acceptable short‐term failure‐free survival with fewer observed high‐grade complications than salvage prostatectomy. Salvage cryoablation also appeared feasible in select patients with low‐volume nodal or metastatic disease. These findings are hypothesis‐generating and require prospective validation.
- Open Access
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Health Literacy Trends and Associations with Transition Readiness in Youth with Spinal Dysraphism
ObjectiveTo assess whether health literacy in young people with spinal dysraphism changes over time and whether such changes were associated with transition readiness. MethodsWe performed a retrospective longitudinal study of prospectively collected patient-reported outcomes from patients ≥12-years-old between May 2019 and February 2024 in a multi-disciplinary spina bifida clinic. Our primary exposure was health literacy, measured with the 4-item BRIEF Health Literacy Screening Tool. Our primary outcome was transition readiness, assessed with the 20-item Transition Readiness Assessment Questionnaire (TRAQ). Repeated measures linear mixed effects models assessed trends in health literacy over time and their association with TRAQ score at each timepoint, adjusting for demographic and clinical variables. An interaction term between health literacy and time was used to evaluate if increasing literacy over time was associated with greater transition readiness. ResultsAmong 248 patients (baseline median age 15.6 years, 52% female, 60% with myelomeningocele), median follow-up was 2.6 years (IQR 1.5-3.6). Health literacy improved significantly over time and was positively associated with older baseline age. Older age at baseline and better baseline health literacy were significantly associated with higher TRAQ score. The interaction term between adequate health literacy and time was significant, suggesting that those with faster improvement in health literacy have higher TRAQ scores. ConclusionsAmong young people with spinal dysraphism, health literacy is a significant and potentially modifiable factor for increasing transition readiness.
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHealth Literacy Trends and Associations with Transition Readiness in Youth with Spinal Dysraphism
ObjectiveTo assess whether health literacy in young people with spinal dysraphism changes over time and whether such changes were associated with transition readiness. MethodsWe performed a retrospective longitudinal study of prospectively collected patient-reported outcomes from patients ≥12-years-old between May 2019 and February 2024 in a multi-disciplinary spina bifida clinic. Our primary exposure was health literacy, measured with the 4-item BRIEF Health Literacy Screening Tool. Our primary outcome was transition readiness, assessed with the 20-item Transition Readiness Assessment Questionnaire (TRAQ). Repeated measures linear mixed effects models assessed trends in health literacy over time and their association with TRAQ score at each timepoint, adjusting for demographic and clinical variables. An interaction term between health literacy and time was used to evaluate if increasing literacy over time was associated with greater transition readiness. ResultsAmong 248 patients (baseline median age 15.6 years, 52% female, 60% with myelomeningocele), median follow-up was 2.6 years (IQR 1.5-3.6). Health literacy improved significantly over time and was positively associated with older baseline age. Older age at baseline and better baseline health literacy were significantly associated with higher TRAQ score. The interaction term between adequate health literacy and time was significant, suggesting that those with faster improvement in health literacy have higher TRAQ scores. ConclusionsAmong young people with spinal dysraphism, health literacy is a significant and potentially modifiable factor for increasing transition readiness.
- Open Access
- 17 March 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (3) , 376
Lower Urinary Tract Symptom Scores Among Patients Presenting for Gender Affirming Orchiectomy: An Exploratory Analysis
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.
- 17 March 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (3) , 376
Open AccessLower Urinary Tract Symptom Scores Among Patients Presenting for Gender Affirming Orchiectomy: An Exploratory Analysis
Current literature on baseline voiding function in gender-diverse patients assigned male at birth (AMAB) is limited. We conducted a retrospective analysis of patients presenting for gender-affirming orchiectomy consultation between 2021 and 2024 who completed the American Urological Association symptom score (AUA-SS) questionnaire to characterize baseline urinary symptoms and identify factors associated with symptom-related bother. Demographics, hormone therapy characteristics, and comorbidities were collected. Bother score was analyzed as both an ordinal variable (score 0 = “delighted” to 6 = “terrible”) and dichotomized (no bother = “delighted” or “pleased” and some bother = “mostly satisfied” to “terrible”). Twenty-six patients met the inclusion criteria, with a median age of 28 years. Overall symptom burden was low (median AUA-SS 4, IQR 2–7.3), with frequency and nocturia reported most commonly. Despite mild symptoms, most patients did not select the lowest possible bother score (“delighted”). Total AUA-SS and bother were not significantly associated with hormone therapy type or duration. In contrast, those with a documented history of anxiety, depression, or bipolar disorder had significantly higher bother score compared to those without (mean rank 15.3 vs. 9.6, p = 0.04). In this single-center cohort, urinary symptoms were generally mild among AMAB patients seeking gender-affirming orchiectomy. Psychiatric history was associated with a higher bother score, though this relationship was no longer significant when bother was dichotomized. These findings suggest behavioral factors may influence how urinary symptoms are experienced and reported in this population. These findings are exploratory and warrant validation in larger cohorts.
- Open Access
- 7 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1
Author Correction: Current era HOLEP with MOSES 2.0 technology compared to the gold standard TURP
- 7 July 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1
Open AccessAuthor Correction: Current era HOLEP with MOSES 2.0 technology compared to the gold standard TURP
- Open Access
- 20 June 2025
- Published by Wiley in The Prostate
- Vol. 85 (12) , 1114-1120
Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance
Background: Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.Methods: Patients considered AS‐eligible (NCCN low‐favorable intermediate risk) but proceeded to RP from February 2012 to September 2024 were identified from our prospective institutional database. Outcomes were classified by presence or absence of APF at RP, which was defined as grade group (GG) ≥ 3, pT3b, or pN1 disease. Previously established genomic signatures of interest were compared between the two groups. Scaled multivariable logistic regression was performed to evaluate associations between multiple genomic classification systems and the outcome of APF.Results: There were 184 AS‐eligible patients, of whom 153 (83.2%) had favorable intermediate risk disease and 31 (16.8%) had low risk disease. There were 41 patients (22.3%) who had APF at RP. The incidence of favorable intermediate risk disease did not differ between those with and without APF (80.5% vs. 83.9%, p = 0.64). Patients with APF had a higher baseline PSA (5.6 ng/mL vs. 4.9 ng/mL, p = 0.01) and Decipher score (0.55 vs. 0.41, p = 0.004) compared to those without APF. On scaled logistic regression with adjustment for log‐transformed PSA, the Decipher score, PTEN loss, activated CD4, and ERG positive rate were significantly associated with APF (OR 1.61, 95% CI 1.11–2.32, p = 0.01). Of ten other previously published genomic classifiers, nine were significantly associated with APF.Conclusion: AS‐eligible patients with APF at RP demonstrate differences in gene expression when compared to those without APF. We established that multiple existing genomic classifiers not previously studied in this context demonstrate the ability to predict APF in this patient population. Inclusion of genomics in the risk stratification of AS‐eligible patients has the potential to better inform clinical decisions.
- 20 June 2025
- Published by Wiley in The Prostate
- Vol. 85 (12) , 1114-1120
Open AccessGenomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance
Background: Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.Methods: Patients considered AS‐eligible (NCCN low‐favorable intermediate risk) but proceeded to RP from February 2012 to September 2024 were identified from our prospective institutional database. Outcomes were classified by presence or absence of APF at RP, which was defined as grade group (GG) ≥ 3, pT3b, or pN1 disease. Previously established genomic signatures of interest were compared between the two groups. Scaled multivariable logistic regression was performed to evaluate associations between multiple genomic classification systems and the outcome of APF.Results: There were 184 AS‐eligible patients, of whom 153 (83.2%) had favorable intermediate risk disease and 31 (16.8%) had low risk disease. There were 41 patients (22.3%) who had APF at RP. The incidence of favorable intermediate risk disease did not differ between those with and without APF (80.5% vs. 83.9%, p = 0.64). Patients with APF had a higher baseline PSA (5.6 ng/mL vs. 4.9 ng/mL, p = 0.01) and Decipher score (0.55 vs. 0.41, p = 0.004) compared to those without APF. On scaled logistic regression with adjustment for log‐transformed PSA, the Decipher score, PTEN loss, activated CD4, and ERG positive rate were significantly associated with APF (OR 1.61, 95% CI 1.11–2.32, p = 0.01). Of ten other previously published genomic classifiers, nine were significantly associated with APF.Conclusion: AS‐eligible patients with APF at RP demonstrate differences in gene expression when compared to those without APF. We established that multiple existing genomic classifiers not previously studied in this context demonstrate the ability to predict APF in this patient population. Inclusion of genomics in the risk stratification of AS‐eligible patients has the potential to better inform clinical decisions.
- 8 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-6
Current era HOLEP with MOSES 2.0 technology compared to the gold standard TURP
Purpose Bipolar TURP is regarded as the gold standard for treatment of BPH. Historically, when compared to HOLEP, bTURP has been found to have shorter operative times and is considered more efficient. We sought to compare the efficiency, efficacy, and safety of current era HOLEP with MOSES 2.0 technology (MOLEP) and bTURP. Methods We performed a retrospective review of patients who underwent bTURP or MOLEP at our institution between 2018 and 2023. Preoperative, intraoperative, and postoperative characteristics were collected for analysis. Analysis was done with SPSS software with significance defined as p < 0.05. Results We identified 195 bTURPs and 918 MOLEPs performed at our institution. Men undergoing MOLEP had significantly higher pre-op prostate volume and resected weight (61 ml v 123 ml and 15 g v 70 g, p < 0.001, respectively) when compared to bTURP patients. MOLEP was completed in significantly less OR and procedure time compared to bTURP (66 min vs. 73 min, p < 0.001; 90 min vs. 111 min, p = 0.026, respectively). These results remained significant when controlling for age and prostate volume. At a mean follow up of 3.7 months, HOLEP patients were significantly more likely to be medication (0 vs. 35.84% p < 0.001) and catheter free post-operatively (0.95% vs. 5.68%, p < 0.001) compared to bTURP. Conclusion In our contemporary cohort, MOLEP is faster and more efficient than bTURP. These findings remained significant despite being performed on larger prostates and in patients more likely to be anticoagulated. Furthermore, MOLEP patients are more likely to remain catheter and medication free at follow-up when compared to bTURP.
- 8 November 2024
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-6
Current era HOLEP with MOSES 2.0 technology compared to the gold standard TURP
Purpose Bipolar TURP is regarded as the gold standard for treatment of BPH. Historically, when compared to HOLEP, bTURP has been found to have shorter operative times and is considered more efficient. We sought to compare the efficiency, efficacy, and safety of current era HOLEP with MOSES 2.0 technology (MOLEP) and bTURP. Methods We performed a retrospective review of patients who underwent bTURP or MOLEP at our institution between 2018 and 2023. Preoperative, intraoperative, and postoperative characteristics were collected for analysis. Analysis was done with SPSS software with significance defined as p < 0.05. Results We identified 195 bTURPs and 918 MOLEPs performed at our institution. Men undergoing MOLEP had significantly higher pre-op prostate volume and resected weight (61 ml v 123 ml and 15 g v 70 g, p < 0.001, respectively) when compared to bTURP patients. MOLEP was completed in significantly less OR and procedure time compared to bTURP (66 min vs. 73 min, p < 0.001; 90 min vs. 111 min, p = 0.026, respectively). These results remained significant when controlling for age and prostate volume. At a mean follow up of 3.7 months, HOLEP patients were significantly more likely to be medication (0 vs. 35.84% p < 0.001) and catheter free post-operatively (0.95% vs. 5.68%, p < 0.001) compared to bTURP. Conclusion In our contemporary cohort, MOLEP is faster and more efficient than bTURP. These findings remained significant despite being performed on larger prostates and in patients more likely to be anticoagulated. Furthermore, MOLEP patients are more likely to remain catheter and medication free at follow-up when compared to bTURP.